ICBP recorded 4Q22 revenue of IDR 15.9 trillion, bringing FY22 revenue to grow 14.1% YoY to IDR 64.8 trillion. In FY22, all segments solidly grew, fueled by high volume and ASP, with the Food Seasonings segment leading the growth at 17.8% YoY.
JPFA posted 4Q22 sales of IDR12.2 trillion (-1.1% QoQ; +0.9% YoY). Gross profit contracted by 26.1% YoY to IDR 1.5 trillion in 4Q22 due to higher production costs (+13.5% YoY), resulting in a lower GPM of 12.6%.
AALI’s profit performance has shown improvement in 4Q22, with gross profit growing 38.1% QoQ along with growth in operating profit (+63.9% QoQ) and net profit (+25.6% QoQ).
In 4Q22, SIDO managed to record a revenue of IDR 1.2 trillion (+25.0% QoQ; +0.6% YoY) driven by higher sales in the Herbal & Supplement segment (+5.6% YoY) as demand for Tolak Angin increased.
MAPI’s sales were recorded at IDR6.6 trillion in 3Q22 (-0.6% QoQ; +123.1% YoY), and the 9M22 cumulatively grew by 55.8% YoY, supported by the growth of the Sports & Leisure, Fashion, Health & Beauty, Food & Beverage, and Digital Devices segments. As of 3Q22, MAPI has opened 91 new stores.
Throughout 9M22, KLBF managed to record sales of 10.9% YoY to IDR21.2 trillion. All segments equally experienced growth, with the Distribution and Logistic Segments leading the growth by 13.8% YoY.
MYOR recorded 3Q22 sales of IDR7.8 trillion (+15.7% QoQ; +16.6% YoY), with net profit recorded to have a significant increase in 3Q22 by IDR431.5 billion (+24.3% QoQ; +811.0% YoY). As for 3Q22, the company recorded margins higher than the same period last year.
The Herbal Medicine and Supplements industry is experiencing a decline in demand due to high inflation, which pressures people’s purchasing power. This can be seen within SIDO’s Herbal Medicine & Supplements segment sales in 3Q22, which decreased by 5.5% YoY.
Throughout 1H22, ERAA posted sales growth of 9.6% YoY while net profit contracted by 9.1% YoY. Almost all segments grew but only Operator Product segment contracted 21.2% YoY.
